Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / Jan / Tracking Liver Disease with Top-Down Proteomics
Omics Translational Science Clinical Mass Spectrometry News and Research

Tracking Liver Disease with Top-Down Proteomics

Proteoform biomarkers provide new insights into liver cirrhosis progression

01/20/2025 1 min read

Share

Credit: Neil L. Kelleher

Research has identified specific proteoform signatures in blood plasma that could help monitor the progression of liver cirrhosis and predict its transition to advanced stages. 

Using blood samples from 30 patients across three stages of cirrhosis – compensated, compensated with portal hypertension, and decompensated – the researchers employed top-down mass spectrometry (TDP) to analyze intact proteins, preserving their full structure and post-translational modifications (PTMs). This approach identified over 2,800 proteoforms, with distinct changes in proteins such as fibrinogen, apolipoprotein A-I, and haptoglobin correlating with disease progression.

“Proteoforms are distinct versions of a protein, arising from variations in gene sequence, RNA splicing, and protein processing. Identifying and quantifying these proteoforms is crucial for understanding their roles in liver cirrhosis,” explained Neil L. Kelleher, lead author and Walter and Mary E. Glass Professor of Molecular Biosciences at Northwestern University, in a press release.

The findings reveal that proteoform modifications, such as truncations and phosphorylation, provide a molecular snapshot of how cirrhosis affects liver function over time. For example, fibrinogen proteoforms involved in blood clotting exhibited stage-dependent changes, reflecting worsening liver dysfunction and increased inflammation as the disease advanced.

Unlike traditional liver function tests or imaging, which may miss subtle biochemical changes, proteomic profiling allows for more precise tracking of disease progression. The ability to detect early molecular changes could enable clinicians to intervene sooner, potentially improving patient outcomes.

“By identifying specific proteoform signatures linked to disease progression, we move closer to personalized medicine for liver cirrhosis patients,” said Kelleher.

The study also underscores the power of top-down proteomics in translational research. By analyzing intact proteins, the approach provides deeper insights into the molecular mechanisms driving liver failure, paving the way for the development of targeted therapies.

“This study typifies how CLP enables translational science across Northwestern’s campuses,” Kelleher noted. “We bring best-in-class technology platforms from the basic sciences into collaboration with key, unmet needs seen by our Feinberg clinicians every day.”

Future work will focus on validating these proteoform signatures in larger patient cohorts and exploring their potential for guiding therapeutic strategies.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.